Ads
related to: renal cell carcinoma treatment- FAQs
Find FAQs For This Treatment
Option On The Official Patient Site
- How This Treatment Works
Learn More About How This
FDA-Approved Treatment Works.
- Dosing Information
Get Dosing And Treatment
Schedule Information.
- Clinical Trial Info
Review Clinical Trial Results For
This FDA-Approved Treatment Option.
- FAQs
Search results
Wistar Scientists Develop Novel Antibody Treatment | Newswise
Newswise· 2 days agoPHILADELPHIA — (June 04, 2024) — Advanced clear cell renal cell carcinoma (ccRCC) is a deadly form...
Scientists develop novel antibody treatment for kidney cancer
Medical Xpress· 1 day agoAntibody therapies called bispecific T cell engagers (BTEs) have emerged as effective treatments for some blood cancers but have been more difficult to ...
GRIT and Quangang announce IL-2 T-cell therapy partnership
Pharmaceutical Technology via Yahoo Finance· 2 days agoQuanqi (125SER) is a marketed human Interleukin-2 used in treating solid tumours including renal ...
Dual Immunotherapy Improves Response Rates in Gynecologic Clear Cell Cancers
MedPage Today· 2 days agoAt a median follow-up of 11.3 months, the overall response rate (ORR) among the 30 patients who...
EMA Panel Nods to Seven New Cancer Drugs
Medscape· 6 days agoThe drugs include an anti–PD-L1 monoclonal antibody, a biosimilar, and five generics, with indications covering a wide spectrum of cancers.
GRIT and Quangang Forge Strategic Partnership to Accelerate Localization of Interleukin-2
The Pilot News· 5 days agoCo., Ltd. (GRIT) and Shandong Quangang Pharmaceutical Co., Ltd. (Quangang) announced the establishment of a formal strategic partnership to leverage both parties' R&D capabilities in innovative ...
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R)...
Digital Journal· 2 days agoAt a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis ...
Newswise Expert | Toni Choueiri, Dana-Farber Cancer Institute
Newswise· 16 hours agoDr. Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 4 days ago(the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune ...
Better Prediction of Bladder Cancer Treatment Outcomes
MedPage Today· 6 days agoA study in the Journal of Precision Oncology indicates that MIR145 core promoter methylation in...
